Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Samuel Fingas"'
Autor:
Constantina Pitsillides, Maimoona Ali, Hayley Evans, Anna Nicholson-Lailey, Samuel Fingas, James Davies
Publikováno v:
Poster Presentations.
Publikováno v:
The Clinical Teacher. 17:705-710
Background End-of-life discussions are associated with improved quality of care for patients. In the UK, the General Medical Council outlines a requirement for medical graduates to involve patients and their families in discussions on their care at t
Publikováno v:
BMJ supportivepalliative care. 10(3)
Opioid-induced constipation (OIC) is common and can significantly affect quality of life. Naloxegol and methylnaltrexone are peripherally acting µ-opioid receptor antagonists (PAMORAs) which are effective for the management of OIC. We report on a ca
Publikováno v:
Poster presentations.
Background In keeping with the ‘Care of dying adults in the last days of life’ NICE guidelines, inpatients are consistently prescribed anticipatory medications. However, decisions for inpatients discharged home were unclear. Evaluating clinical p
44 Service evaluation of the use of fluids at end of life across two inpatient palliative care units
Autor:
Constantina Pitsillides, Eleanor Smith, Olivia Liddle, Samuel Fingas, Roseleen Sheehan, Jenny Brocklebank, Rachel Parry
Publikováno v:
Poster presentations.
Background ‘Five Priorities of Care’ requires an individualised plan for hydration at end of life and discussion with patients/those important to them. However there is little research surrounding this topic and the use of fluids is often depende
Autor:
Rachel Parry, Samuel Fingas
Publikováno v:
Journal of Pain and Symptom Management. 53:e4-e5
Publikováno v:
BMJ Supportive & Palliative Care. 4:A7.1-A7
Background Opioid-induced constipation is common in palliative care. The evidence base for most laxatives and rectal interventions is poor, but for sc methylnaltrexone is good. Patient choice is important for individualising treatment. Aims To identi
Autor:
Vanessa Spawton, Sian Richardson, Samuel Fingas, Elizabeth L. Miller, Anne-Marie Bourke, Sam H Ahmedzai
Publikováno v:
BMJ Supportive & Palliative Care. 4:A50.2-A50
Background PecFent ® is a powerful fast-acting fentanyl nasal spray which is used for breakthrough cancer pain. When it is not administered correctly or titrated quickly enough, we suspect aspects of patient care may suffer, with sub-optimal pain co
Publikováno v:
BMJ Supportive & Palliative Care. 4:A69.2-A69
Background Ketamine is a potent analgesic with potentially serious adverse effects (eg dysphoria, bladder dysfunction), being used in palliative medicine. Its evidence base is limited and a recent RCT using the SC route in cancer pain failed to show